2025-2026

CHBRP generally analyzes introduced bills prior to their first Senate or Assembly Health Committee hearing. Completed CHBRP analyses (and the analyzed bill language) are available at http://chbrp.org/analysis/completed-analyses. As bills move through the Legislature, bills may be significantly amended, which may alter CHBRP’s projected impacts. The table, below, indicates the version of each analyzed bill and the extent to which CHBRP’s analyses remain relevant. Amended bill language and the bill status are available at http://leginfo.legislature.ca.gov/.

CHBRP’s analyses may still be of use after the legislative cycle concludes in order to inform future legislation, the implementation of analyzed legislation that is signed into law or included in California’s budget, and the ongoing evaluation of relevant health benefit mandates and repeals.

Bill Number Bill Author Bill Title Current location Bill amended since CHBRP analysis? Which portions of CHBRP’s analysis remain relevant?
AB 298 Bonta
Cost Sharing
 View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP's analysis remain relevant.
AB 350 Bonta
Fluoride treatment
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/23/2025 – Amended language would require coverage of fluoride varnish billed as a medical benefit without cost sharing. All portions of CHBRP's analysis remain relevant.
AB 432 Bauer-Kahan
Menopause
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/27/2025 – Amended language modifies the language regarding continuing medical education. All portions of CHBRP's analysis remain relevant.
AB 546 Caloza
HEPA purifiers and filters
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/1/2025 – Amended language would narrow the bill requirements to include coverage for only HEPA purifiers under $500. The amendments also remove the prohibition on cost sharing, and limit eligibility for the benefit to only enrollees with health plans or policies in the large group market who are located in counties where a local or state emergency has been declared due to wildfires. CHBRP completed an updated fiscal analysis of the bill as amended on 5/1/2025 at the request of the Legislature, which was published on 5/13/2025.
AB 554 González
Antiretroviral drugs, drug devices, and drug products
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/23/2025 – Amended language narrows the mandate to require coverage without cost sharing for only preexposure prophylaxis under grandfathered and nongrandfathered plans. Because coverage for preexposure prophylaxis is already required under the California and Federal Preventive Service Acts, the bill would only impact grandfathered plans. The amendments would result in a decrease in the projected fiscal impact from CHBRP’s analysis. All other portions of CHBRP’s analysis remain relevant.
AB 575 Arambula
Obesity Prevention Treatment Parity Act
 View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP's analysis remain relevant.
AB 1032 Harabedian and Rivas
Coverage for behavioral health visits
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/05/2025 – Along with other technical changes, the amended language specifies that coverage applies only to large group plans (removes individual and small group plans) and adds coverage for members in the California State Teachers’ Retirement System (CalSTRS) who receive a health care benefit under CalSTRS. These changes may impact estimated costs but the magnitude of such changes is unknown. All other portions of CHBRP’s analysis remain relevant.
SB 40 Wiener
Insulin
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/23/2025 – April amended language would delay implementation for the small group and individual markets until 2027 and would states that plans and policies would be required to cover at least one of each drug type of insulin without step therapy. The May 23rd amended language would, for individual and small group plans and policies that maintain a drug formulary grouped into tiers, require at least two insulins of each form type and concentration to be placed on Tier 1 or Tier 2. When these conditions are met, the cost sharing cap only applies to insulins on Tier 1 and Tier 2. This amendment could result in some enrollees experiencing cost sharing above the $35 copay cap and therefore would decrease the estimated fiscal estimates included in CHBRP’s analysis. All other portions of CHBRP’s analysis remain relevant.
SB 242 Blakespear
Medicare supplement coverage: open enrollment periods
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/05/2025 – The bill amendment moves away from “attained age" to "age at issue" (which is another popular way to set premiums in this market). CHBRP anticipates the amended language would result in a smaller but still significant premium increase because there would be a barrier to enrollment in Medicare Supplement plans for older beneficiaries - it would not be as worthwhile for beneficiaries to wait until they are older. However, the guaranteed issue provision remaining in SB 242 would still cause some people to choose to wait to purchase Medicare Supplement plans. The amended language would likely reduce adverse selection, which in turn should reduce the magnitude of premium increases and thus increase enrollment of lower risk, less costly individuals.
SB 257 Wahab
PARENT Act
 View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP's analysis remain relevant.
SB 535 Richardson
Obesity Treatment Parity Act
 View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP's analysis remain relevant.
SB 626 Smallwood-Cuevas
Perinatal health screenings and treatment
 View status on https://leginfo.legislature.ca.gov/ Yes Bill amended – 5/05/2025 – Amended language would encourage but no longer require health plans and policies to improve screening and treatment for perinatal mental health conditions through the use of medications and digital therapeutics approved by the FDA for perinatal mental health conditions. Amended language would also allow providers to adhere to guidelines or standards adopted by other recognized professional bodies if adherence to ACOG clinical guidelines does not align with a provider’s scope of practice. The background and medical effectiveness sections of CHBRP’s analysis remain relevant.
Bill Number Bill Author Bill Title Current location Amended Which portions of CHBRP’s analysis remain relevant?